• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于复杂临床试验中对数秩统计量的样本量。

Sample sizes based on the log-rank statistic in complex clinical trials.

作者信息

Lakatos E

机构信息

Biostatistics Research Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892.

出版信息

Biometrics. 1988 Mar;44(1):229-41.

PMID:3358991
Abstract

The log-rank test is frequently used to compare survival curves. While sample size estimation for comparison of binomial proportions has been adapted to typical clinical trial conditions such as noncompliance, lag time, and staggered entry, the estimation of sample size when the log-rank statistic is to be used has not been generalized to these types of clinical trial conditions. This paper presents a method of estimating sample sizes for the comparison of survival curves by the log-rank statistic in the presence of unrestricted rates of noncompliance, lag time, and so forth. The method applies to stratified trials in which the above conditions may vary across the different strata, and does not assume proportional hazards. Power and duration, as well as sample sizes, can be estimated. The method also produces estimates for binomial proportions and the Tarone-Ware class of statistics.

摘要

对数秩检验常用于比较生存曲线。虽然二项比例比较的样本量估计已适用于诸如不依从、延迟时间和交错入组等典型临床试验条件,但在使用对数秩统计量时的样本量估计尚未推广到这类临床试验条件。本文提出了一种在存在无限制的不依从率、延迟时间等情况下,通过对数秩统计量估计生存曲线比较样本量的方法。该方法适用于分层试验,其中上述条件在不同层可能有所不同,且不假定风险比例。可以估计检验效能、持续时间以及样本量。该方法还能对二项比例和Tarone-Ware统计量类别进行估计。

相似文献

1
Sample sizes based on the log-rank statistic in complex clinical trials.基于复杂临床试验中对数秩统计量的样本量。
Biometrics. 1988 Mar;44(1):229-41.
2
Sample size calculation in survival trials accounting for time-varying relationship between noncompliance and risk of outcome event.考虑不依从与结局事件风险之间随时间变化关系的生存试验中的样本量计算。
Clin Trials. 2006;3(4):349-59. doi: 10.1177/1740774506069155.
3
Sample size determination for comparing several survival curves with unequal allocations.用于比较几个不等分配的生存曲线的样本量确定。
Stat Med. 2004 Jun 15;23(11):1793-815. doi: 10.1002/sim.1771.
4
Designing complex group sequential survival trials.设计复杂的序贯群组生存试验。
Stat Med. 2002 Jul 30;21(14):1969-89. doi: 10.1002/sim.1193.
5
Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion.基于 Edgeworth 展开的单样本对数秩检验及其校正的 II 期癌症临床试验。
Contemp Clin Trials. 2011 Jan;32(1):108-13. doi: 10.1016/j.cct.2010.09.009. Epub 2010 Oct 1.
6
Some design issues of strata-matched non-randomized studies with survival outcomes.具有生存结局的分层匹配非随机研究的一些设计问题。
Stat Med. 2006 Dec 15;25(23):3949-59. doi: 10.1002/sim.2521.
7
Biostatistics in clinical trials: Part 2. Determining sample sizes for clinical trials.临床试验中的生物统计学:第2部分。确定临床试验的样本量。
Oncology (Williston Park). 1989 Aug;3(8):39-46; discussion 48, 51.
8
Sample size estimation for the van Elteren test--a stratified Wilcoxon-Mann-Whitney test.范埃尔特伦检验的样本量估计——一种分层威尔科克森-曼-惠特尼检验。
Stat Med. 2006 Aug 15;25(15):2675-87. doi: 10.1002/sim.2441.
9
Sample size re-estimation in group-sequential response-adaptive clinical trials.成组序贯反应自适应临床试验中的样本量重新估计
Stat Med. 2003 Dec 30;22(24):3843-57. doi: 10.1002/sim.1677.
10
Combining stratified and unstratified log-rank tests in paired survival data.配对生存数据中分层和非分层对数秩检验的联合应用。
Stat Med. 2010 Jul 20;29(16):1735-45. doi: 10.1002/sim.3921.

引用本文的文献

1
Simulations-Based Least Required Sample Size and Power in Clinical Trials with Time-to-Event endpoint and Variable Hazard.基于模拟的具有事件发生时间终点和可变风险的临床试验中所需的最小样本量和检验效能
Int J Epidemiol Public Health Res. 2024;5(3). Epub 2024 Sep 20.
2
Capecitabine metronomic chemotherapy for metastatic colorectal cancer patients reaching NED: A protocol for a prospective, randomized, controlled trial.卡培他滨节拍化疗用于达到无疾病证据的转移性结直肠癌患者:一项前瞻性、随机、对照试验方案
PLoS One. 2025 Apr 21;20(4):e0320591. doi: 10.1371/journal.pone.0320591. eCollection 2025.
3
Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation: An Open-Label, Multicenter, Randomized Controlled Clinical Trial.
间充质干细胞序贯输注预防单倍体造血干细胞移植中移植物抗宿主病:一项开放标签、多中心、随机对照临床试验
J Clin Oncol. 2025 Jun 10;43(17):1997-2006. doi: 10.1200/JCO-24-02119. Epub 2025 Apr 15.
4
Prognostic impact of psychoeducation program completion on inpatients with schizophrenia: a pilot cohort study.心理教育项目完成情况对精神分裂症住院患者的预后影响:一项前瞻性队列研究。
BMC Psychiatry. 2025 Jan 17;25(1):50. doi: 10.1186/s12888-024-06397-5.
5
An overlap-weighted analysis on the association of constipation symptoms with disease progression and survival in amyotrophic lateral sclerosis: a nested case-control study.肌萎缩侧索硬化症中便秘症状与疾病进展及生存关联的重叠加权分析:一项巢式病例对照研究
Ther Adv Neurol Disord. 2025 Jan 9;18:17562864241309811. doi: 10.1177/17562864241309811. eCollection 2025.
6
Association between Poor Outcomes and Risk of Refeeding Syndrome among Patients Urgently Admitted to the High Dependency Unit: A Single-Center Cohort Study in Japan.紧急入住重症监护病房的患者不良结局与再喂养综合征风险的相关性:日本单中心队列研究。
Nutrients. 2024 Sep 28;16(19):3287. doi: 10.3390/nu16193287.
7
Using non-inferiority test of proportions in design of randomized non-inferiority trials with time-to-event endpoint with a focus on low-event-rate setting.在具有事件发生时间终点的随机非劣效性试验设计中,使用比例的非劣效性检验,重点关注低事件率情况。
Clin Trials. 2025 Apr;22(2):131-141. doi: 10.1177/17407745241284786. Epub 2024 Oct 12.
8
Sample Size Reestimation in Stochastic Curtailment Tests With Time-to-Events Outcome in the Case of Nonproportional Hazards Utilizing Two Weibull Distributions With Unknown Shape Parameters.在非比例风险情况下,利用两个形状参数未知的威布尔分布,对具有事件发生时间结局的随机截尾试验进行样本量重新估计。
Pharm Stat. 2025 Jan-Feb;24(1):e2429. doi: 10.1002/pst.2429. Epub 2024 Aug 18.
9
Postoperative radiotherapy with docetaxel versus cisplatin for high-risk oral squamous cell carcinoma: a randomized phase II trial with exploratory analysis of ITGB1 as a potential predictive biomarker.术后多西他赛联合顺铂放疗与单纯手术治疗高危口腔鳞状细胞癌的随机Ⅱ期临床试验:以 ITGB1 为潜在预测生物标志物的探索性分析
BMC Med. 2024 Jul 29;22(1):314. doi: 10.1186/s12916-024-03541-6.
10
The Influence of Pubertal Development on Autoantibody Appearance and Progression to Type 1 Diabetes in the TEDDY Study.TEDDY研究中青春期发育对自身抗体出现及1型糖尿病进展的影响
J Endocr Soc. 2024 May 24;8(7):bvae103. doi: 10.1210/jendso/bvae103. eCollection 2024 May 23.